A Study of LM-24C5 For Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLaNova Medicines Limited
About this trial
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Eligibility criteria
Qualifiers
Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any study related procedures.
Aged ≥18 years old when sign the ICF, male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose.
Life expectancy ≥ 3 months.
Disqualifiers
Participate in any other clinical trial within 28 days prior to 1st dosing of LM-24C5.
Any prior treatments towards the investigational target.
Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-24C5, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. the following treatments have different time limits.
Any adverse event from prior anti-tumor therapy has not yet recovered to≤ grade 1 of CTCAE v5.0.
Trial design
Treatments tested in this trial
- LM-24C5
Treatment groups
49 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov